Publications
Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM. Rectal cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2012. PMID: 23221790
Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nature reviews. Drug discovery. 2012. PMID: 23197039
Gubens MA. Treatment updates in advanced thymoma and thymic carcinoma. Current treatment options in oncology. 2012. PMID: 22961051
Chou J, Werb Z. MicroRNAs play a big role in regulating ovarian cancer-associated fibroblasts and the tumor microenvironment. Cancer discovery. 2012. PMID: 23230184
Miaskowski C, Cooper B, Paul SM, West C, Langford D, Levine JD, Abrams G, Hamolsky D, Dunn L, Dodd M, Neuhaus J, Baggott C, Dhruva A, Schmidt B, Cataldo J, Merriman J, Aouizerat BE. Identification of patient subgroups and risk factors for persistent breast pain following breast cancer surgery. The journal of pain. 2012. PMID: 23182226
Baikaidi M, Chung SS, Tallman MS, Damon LE, Walker AR, Marcucci G, Sholi AM, Morris GJ. A 75-year-old woman with thoracic spinal cord compression and chloroma (granulocytic sarcoma). Seminars in oncology. 2012. PMID: 23206848
Hussein E, Borno HT, van Aalst JA. Cleft Lip and Palate Diagnosis and Management Birthing and Building Nascent Cleft Teams in Developing Countries. 2012. PMID:
Sanou MP, De Groot AS, Murphey-Corb M, Levy JA, Yamamoto JK. HIV-1 Vaccine Trials: Evolving Concepts and Designs. The open AIDS journal. 2012. PMID: 23289052
Ryan CJ, Cheng ML. Abiraterone acetate for the treatment of prostate cancer. Expert opinion on pharmacotherapy. 2012. PMID: 23199349
Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2012. PMID: 23197589
Dunn LB, Aouizerat BE, Langford DJ, Cooper BA, Dhruva A, Cataldo JK, Baggott CR, Merriman JD, Dodd M, West C, Paul SM, Miaskowski C. Cytokine gene variation is associated with depressive symptom trajectories in oncology patients and family caregivers. European journal of oncology nursing : the official journal of European Oncology Nursing Society. 2012. PMID: 23187335
Neel DS, Bivona TG. Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012. PMID: 23172883
Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012. PMID: 23169517
Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012. PMID: 23169510
O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012. PMID: 23169518
Gautam Borthakur, Leslie Popplewell, Michael Boyiadzis, James M. Foran, Uwe Platzbecker, Norbert Vey, Walter B. Roland, Rebecca L. Olin, Azra Raza, Aristotles Giagounidis, Oliver G. Ottmann, Aref Al-Kali, Elias J. Jabbour, Tapan M. Kadia, Guillermo Garcia-Manero, John W. Bauman, Yuehui Wu, Yuan Liu, Dan Schramek, John Z. Zhu, Paul Wissel, Hagop M. Kantarjian. Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease. Blood. 2012. PMID:
Willard Cheng, Elisabeth Lasater, Catherine C Smith, Mouanoutoua Mokang, Yun Bao, Neil Shah. Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples. Blood. 2012. PMID:
James L. Rubenstein, Eric D. Hsi, Jeffrey L. Johnson, Sin-Ho Jung, Barbara Grant, Bruce D. Cheson, Lawrence D. Kaplan. BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance). Blood. 2012. PMID:
Catherine C Smith, Jason Chin, Elisabeth Lasater, Amy L. Paguirigan, Kimberly Lin, Whitney Stewart, Sara Salerno, Lauren E Damon, Mark J. Levis, Alexander E Perl, Kevin Travers, Andrew Kasarskis, Jerald P. Radich, Neil Shah. Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220. Blood. 2012. PMID:
Catherine C Smith, Elisabeth Lasater, Melissa Mccreery, Kimberly Lin, Whitney Stewart, Lauren E Damon, Alexander E Perl, Grace R Jeschke, Mayumi Sugita, Martin Carroll, Scott C. Kogan, Neil Shah. Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants. Blood. 2012. PMID: